Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive advanced gastric cancer
NCT04714190Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in gastric cancer (GC), sponsored by RemeGen. Started Mar 2021; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04714190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714190.